Reevaluation of a weight-based heparin dosing nomogram: Is institution- specific modification necessary?

Annals of Pharmacotherapy

Volumn 31, Issue 12, 1997, Pages 1454-1459

  Schlicht, John R ^a,b   Sunyecz, Lisa ^c   Weber, Robert J ^b,d   Tabas, Gary H ^b   Smith, Roy E ^b  

^a DUQUESNE UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c Uniontown Hospital   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Heparin; Nomogram

Indexed keywords

HEPARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BODY WEIGHT; COHORT ANALYSIS; HEPARINIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NOMOGRAM; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; TREATMENT INDICATION;

EID: 0031469010     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703101202     Document Type: Article

References (19)

1. Raschke RA, Gollihare B. Peirce JC. The effectiveness of implementing the weight-based heparin nomogram as a practice guideline. Arch Intern Med 1996;156:1645-9.
2. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. Ann Intern Med 1993;119:874-81.
3. Gunnarsson PS, Sawyer WT, Montague D, Williams ML, Dupuis RE, Caiola SM. Appropriate use of heparin: empiric vs nomogram-based dosing. Arch Intern Med 1995;155:526-32.
4. Kaplan K, Davison R, Parker M, Maybery B, Feiereisel P, Salinger M. Role of heparin after intravenous thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1987;59:241-4.
5. Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315:1109-14.
6. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287:324-7.
7. Anand S, Ginsberg JS, Kearon C, Gent M, Hirsh J. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med 1996;156:1677-81.
8. Hull RD, Raskob GE, Rosenbloom D, Lemaire J, Pineo GF, Baylis B, et al. Optimal therapeutic level of heparin therapy in patients with venous thromboembolism. Arch Intern Med 1992;152:1589-95.
9. Norman CS, Provan JL, Control and complications of intermittent heparin therapy. Surg Gynecol Obstet 1977;145:338-42.
10. Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987;82:703-13.
11. Conti S, Daschbach M, Blaisdell FW. A comparison of high-dose versus conventional-dose heparin therapy for deep vein thrombosis. Surgery 1982;92:972-7.
12. GUSTO IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631-7.
13. Neuhaus KL, von Essen R, Tebbe U, Jessel A, Heinrichs H, Maurer W, et al. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. Circulation 1994;90:1638-42.
14. Antman EM. Hirudin in acute myocardial infarction: safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994;90:1624-30.
15. Sobel BE. Intracranial bleeding, fibrinolysis, and anticoagulation: causal connections and clinical implications. Circulation 1994;90:2147-52.
16. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108(suppl):258S-75S.
17. Stevenson KJ, Easton AC, Curry A, Thomson JM, Poller L. The reliability of activated partial thromboplastin time methods and the relationship to lipid composition and ultrastructure. Thromb Haemost 1986;55:250-8.
18. D'Angelo A, Seveso MP, D'Angelo SV, Gilardoni F, Dettori AG, Bonini P. Effect of clot-detection methods and reagents on activated partial thromboplastin time (aPTT): implications in heparin monitoring by aPTT. Am J Clin Pathol 1990;94:297-306.
19. Brill-Edwards P, Ginsberg JS, Johnston M. Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993;119:104-9.